Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291526 | 1.00 | FDPS (0.34) | FDPSNFKB1NFKB2RELAEPAS1 | |
| SCHEMBL22861892 | 0.88 | FDPS (0.39) | FDPSNFKB1NFKB2RELAEPAS1 | |
| SCHEMBL22861862 | 0.81 | EP300 (0.31) | EP300 | |
| SCHEMBL22861861 | 0.81 | EP300 (0.31) | EP300 | |
| SCHEMBL22862020 | 0.80 | EP300 (0.32) | EP300 | |
| SCHEMBL22862021 | 0.80 | EP300 (0.32) | EP300 | |
| SCHEMBL22861873 | 0.77 | FDPS (0.30) | FDPSEP300 | |
| SCHEMBL22861874 | 0.77 | FDPS (0.30) | FDPSEP300 | |
| Horminone SCHEMBL22861891 | 0.71 | CYP19A1 (0.45) | FDPSGGPS1CYP19A1EP300TP53 | |
| Horminone SCHEMBL22861860 | 0.71 | CYP19A1 (0.45) | FDPSGGPS1CYP19A1EP300TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | F5, F2, F3 | FDPS 124/4885NFKB1 237/4885NFKB2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.